Proteomics identification of oxidatively modified proteins in the alzheimer’s disease brain and models thereof: Insights into potential mechanisms of neurodegeneration

Oxidative Stress and Age-Related Neurodegeneration

Volumn , Issue , 2005, Pages 1-26

  Butterfield, D Allan ^a   Poon, H Fai ^a   Sultana, Rukhsana ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057912513     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (144)

1. Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A, Van Broeckhoven C. Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet, 1998; 7:43-51.
2. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Rebecca Mant R, Newton P, ROOKE K, Roques P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature, 1991; 349:704-706.
3. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montes MP, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HAR, Haines JL, Pericak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995; 375:754-760.
4. Slooter AJ, Cruts M, Kalmijn S, Hofman A, Breteler MM, Van Broeckhoven C, van Duijn CM. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol, 1998; 55:964-968.
5. Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellenberg GD. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer’s disease. Ann Neurol, 1995; 38:678-680.
6. Dahiyat M, Cumming A, Harrington C, Wischik C, Xuereb J, Corrigan F, Breen G, Shaw D, St Clair D. Association between Alzheimer’s disease and the NOS3 gene. Ann Neurol, 1999; 46:664-667.
7. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B, Jr., Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet, 1998; 19:357-360.
8. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, Wisniewski HM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem, 1986; 261:6084-6089.
9. Selkoe DJ. Presenilin, Notch, and the genesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci USA, 2001; 98:11039-11041.
10. Coyle JT, Price DL, DeLong MR. Alzheimer’s disease: a disorder of cortical cholinergic innervation. Science, 1983; 219:1184-1190.
11. Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med, 1997; 23:134-147.
12. Lauderback CM, Hackett JM, Huang FF, Keller JN, Szweda LI, Markesbery WR, Butterfield DA. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer’s disease brain: the role of Abeta1-42. J Neurochem, 2001; 78:413-416.
13. Butterfield DA, Lauderback CM. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med, 2002; 32:1050-1060.
14. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging, 2002; 23:655-664.
15. Butterfield DA, Drake J, Pocernich C, Castegna A. Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med, 2001; 7:548-554.
16. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer’s disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging, 2001; 22:187-194.
17. Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitrated proteins in Alzheimer’s disease brain. J Neurochem, 2003; 85:1394-1401.
18. Smith MA, Sayre LM, Monnier VM, Perry G. Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol Chem Neuropathol, 1996; 28:41-48.
19. Smith MA, Richey Harris PL, Sayre LM, Beckman JS, Perry G. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci, 1997; 17:2653-2657.
20. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer’s disease brain. A review. Free Radic Res, 2002; 36:1307-1313.
21. Aksenov MY, Aksenova MV, Butterfield DA, Geddes JW, Markesbery WR. Protein oxidation in the brain in Alzheimer’s disease. Neuroscience, 2001; 103:373-383.
22. Smith MA, Richey PL, Taneda S, Kutty RK, Sayre LM, Monnier VM, Perry G. Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer’s disease. Ann NY Acad Sci, 1994; 738:447-454.
23. Hensley K, Hall N, Subramaniam R, Cole P, Harris M, Aksenov M, Aksenova M, Gabbita SP, Wu JF, Carney JM, Lovell M, Markesbery WR, Butterfield DA. Brain regional correspondence between Alzheimer’s disease histopathology and biomarkers of protein oxidation. J Neurochem, 1995; 65:2146-2156.
24. Boyd-Kimball D, Sultana R, Mohmmad-Abdul H, Butterfield DA. Rodent Abeta(1-42) exhibits oxidative stress properties similar to those of human Abeta(1-42): implications for proposed mechanisms of toxicity. J Alzheimers Dis, 2004; 6:515-525.
25. Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr Neurosci, 2002; 5:229-239.
26. Yatin SM, Varadarajan S, Butterfield DA. Vitamin E prevents Alzheimer’s amyloid beta-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis, 2000; 2:123-131.
27. Butterfield DA. Proteomics: a new approach to investigate oxidative stress in Alzheimer’s disease brain. Brain Res, 2004; 1000:1-7.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology, 1984; 34:939-944.
29. Wellman CL, Sengelaub DR. Cortical neuroanatomical correlates of behavioral deficits produced by lesion of the basal forebrain in rats. Behav Neural Biol, 1991; 56:1-24.
30. Ezrin-Waters C, Resch L. The nucleus basalis of Meynert. Can J Neurol Sci, 1986; 13:8-14.
31. Paxinos G, Watson, C. The Rat Brain in Streotaxic Coordinates. Academic Press, New York, USA, 1998.
32. Link CD. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA, 1995; 92:9368-9372.
33. Link CD, Johnson, C.J., Fonte, V., Paupard, M., Hall, D.H., Styren, S., Mathis, C.A., and Klunk, W.E., Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging, 2001; 22:217-226.
34. Yatin SM, Varadarajan S, Link CD, Butterfield DA. In vitro and in vivo oxidative stress associated with Alzheimer’s amyloid beta-peptide (1-42). Neurobiol Aging, 1999; 20:325-330; discussion 339-342.
35. Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging, 2003; 24:415-420.
36. Flood JF, Morley JE. Age-related changes in footshock avoidance acquisition and retention in senescence accelerated mouse (SAM). Neurobiol Aging, 1993; 14:153-157.
37. Morley JE, Kumar VB, Bernardo AE, Farr SA, Uezu K, Tumosa N, Flood JF. β-amyloid precursor polypeptide in SAMP8 mice affects learning and memory. Peptides, 2000; 21:1761-1767.
38. Takemura M, Nakamura S, Akiguchi I, Ueno M, Oka N, Ishikawa S, Shimada A, Kimura J, Takeda T. Beta/A4 proteinlike immunoreactive granular structures in the brain of senescence-accelerated mouse. Am J Pathol, 1993; 142:1887-1897.
39. Kawamata T, Akiguchi I, Maeda K, Tanaka C, Higuchi K, Hosokawa M, Takeda T. Age-related changes in the brains of senescence-accelerated mice (SAM): association with glial and endothelial reactions. Microsc Res Tech, 1998; 43:59-67.
40. Rabilloud T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, but it still climbs up the mountains. Proteomics, 2002; 2:3-10.
41. Tilleman K, Stevens I, Spittaels K, Haute CV, Clerens S, Van Den Bergh G, Geerts H, Van Leuven F, Vandesande F, Moens L. Differential expression of brain proteins in glycogen synthase kinase-3 transgenic mice: A proteomics point of view. Proteomics, 2002; 2:94-104.
42. Kaji H, Tsuji T, Mawuenyega KG, Wakamiya A, Taoka M, Isobe T. Profiling of Caenorhabditis elegans proteins using two-dimensional gel electrophoresis and matrix assisted laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis, 2000; 21:1755-1765.
43. Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: un amour impossible? Electrophoresis, 2000; 21:1054-1070.
44. Herbert B. Advances in protein solubilization for two-dimensional gel electrophoresis. Electrophoresis, 1999; 20:660-663.
45. Molloy MP. Two-dimensional electrophoresis of membrane proteins using immobilized pH gradients. Anal Biochem, 2000; 280:1-10.
46. Stevens SM, Jr., Kem WR, Prokai L. Investigation of cytolysin variants by peptide mapping: enhanced protein characterization using complementary ionization and mass spectrometric techniques. Rapid Commun Mass Spectrom, 2002; 16:2094-2101.
47. Wagner Y, Sickmann A, Meyer HE, Daum G. Multidimensional nano-HPLC for analysis of protein complexes. J Am Soc Mass Spectrom, 2003; 14:1003-1011.
48. Smolka MB, Zhou H, Purkayastha S, Aebersold R. Optimization of the isotope-coded affinity tag-labeling procedure for quantitative proteome analysis. Anal Biochem, 2001; 297:25-31.
49. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem Rev, 2001; 101:269-295.
50. Butterfield DA, Boyd-Kimball D, Castegna A. Proteomics in Alzheimer’s disease: insights into potential mechanisms of neurodegeneration. J Neurochem, 2003; 86:1313-1327.
51. Hoogland C, Sanchez JC, Tonella L, Binz PA, Bairoch A, Hochstrasser DF, Appel RD. The 1999 SWISS-2DPAGE database update. Nucleic Acids Res, 2000; 28:286-288.
52. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med, 2002; 33:562-571.
53. Poon HF, Castegna A, Farr SA, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, Klein JB, Butterfield DA. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience, 2004; 126:915-926.
54. Sultana R, Butterfield DA. Oxidatively modified GST and MRP1 in Alzheimer’s disease brain: Implications for accumulation of reactive lipid peroxidation products. Neurochem Res, 2004; 29:2215-2220.
55. Castegna A, Aksenov M, Thongboonkerd V, Klein JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA. Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem, 2002; 82:1524-1532.
56. Aksenova MV, Aksenov MY, Payne RM, Trojanowski JQ, Schmidt ML, Carney JM, Butterfield DA, Markesbery WR. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dement Geriatr Cogn Disord, 1999; 10:158-165.
57. Sultana R, Boyd-Kimball D, Poon HF, Cai j, Pierce WM, Klein JB, Markesbery WR, Butterfield DA. Regional redox proteomics to identify oxidized proteins in Alzheimer’s disease brain: A approach to understand pathological and biochemical alterations in AD. Neurobiol Aging, 2005 (in press).
58. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, Butterfield DA. Oxidative modification and down-regulation of Pin 1 Alzheimer’s disease hippocampus: A redox Proteomics analysis. Neurobiol Aging, 2005 (in press).
59. Aksenova M, Butterfield DA, Zhang SX, Underwood M, Geddes JW. Increased protein oxidation and decreased creatine kinase BB expression and activity after spinal cord contusion injury. J Neurotrauma, 2002; 19:491-502.
60. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, Murayama O, Ishiguro K, Tatebayashi Y, Takashima A. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer’s disease. J Neurosci, 2004; 24:2401-2411.
61. Subramaniam R, Roediger F, Jordan B, Mattson MP, Keller JN, Waeg G, Butterfield DA. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J Neurochem, 1997; 69:1161-1169.
62. Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol, 1995; 40:759-766.
63. Scheff SW, Price DA. Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies. Neurobiol Aging, 2003; 24:1029-1046.
64. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer’s disease. Neurosci Lett, 1994; 174:67-72.
65. Beckers CJ, Block MR, Glick BS, Rothman JE, Balch WE. Vesicular transport between the endoplasmic reticulum and the Golgi stack requires the NEM-sensi-tive fusion protein. Nature, 1989; 339:397-398.
66. Stenbeck G. Soluble NSF-attachment proteins. Int J Biochem Cell Biol, 1998; 30:573-577.
67. Wilkinson KD, Tashayev VL, O’Connor LB, Larsen CN, Kasperek E, Pickart CM. Metabolism of the polyubiquitin degradation signal: structure, mechanism, and role of isopeptidase T. Biochemistry, 1995; 34:14535-14546.
68. Hyun DH, Lee MH, Halliwell B, Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration? J Neurochem, 2002; 83:360-370.
69. Castegna A, Thongboonkerd V, Klein J, Lynn BC, Wang YL, Osaka H, Wada K, Butterfield DA. Proteomic analysis of brain proteins in the gracile axonal dystrophy (gad) mouse, a syndrome that emanates from dysfunctional ubiquitin carboxyl-terminal hydrolase L-1, reveals oxidation of key proteins. J Neurochem, 2004; 88:1540-1546.
70. Daleke DL, Lyles JV. Identification and purification of aminophospholipid flip-pases. Biochim Biophys Acta, 2000; 1486:108-127.
71. Mohmmad-Abdul H, Butterfield D. Protection against amyloid beta-peptide (1-42)-induced loss of phospholipid asymmetry in synaptosomal membranes by tricyclodecan-9-xanthogenate (D609) and ferulic acid ethyl ester: implications for Alzheimer’s disease. Biophys Biochem Acta, 2005; 174:140-148.
72. Castegna A, Lauderback CM, Mohmmad-Abdul H, Butterfield DA. Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer’s disease. Brain Res, 2004; 1004:193-197.
73. Davies P. Challenging the cholinergic hypothesis in Alzheimer disease. JAMA, 1999; 281:1433-1434.
74. Lubec G, Nonaka M, Krapfenbauer K, Gratzer M, Cairns N, Fountoulakis M. Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm Suppl, 1999; 57:161-177.
75. Coleman PD, Flood DG. Neuron numbers and dendritic extent in normal aging and Alzheimer’s disease. Neurobiol Aging, 1987; 8:521-545.
76. Arendt T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity. Prog Neurobiol, 2003; 71:83-248.
77. Schutkowski M, Bernhardt A, Zhou XZ, Shen M, Reimer U, Rahfeld JU, Lu KP, Fischer G. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry, 1998; 37:5566-5575.
78. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, Kullertz G, Stark M, Fischer G, Lu KP. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell, 2000; 6:873-883.
79. Ramakrishnan P, Dickson DW, Davies P. Pin1 colocalization with phosphorylated tau in Alzheimer’s disease and other tauopathies. Neurobiol Dis, 2003; 14:251-264.
80. Holzer M, Gartner U, Stobe A, Hartig W, Gruschka H, Bruckner MK, Arendt T. Inverse association of Pin1 and tau accumulation in Alzheimer’s disease hippocampus. Acta Neuropathol (Berl), 2002; 104:471-481.
81. Kurt MA, Davies DC, Kidd M, Duff K, Howlett DR. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol Dis, 2003; 14:89-97.
82. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature, 1999; 399:784-788.
83. Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Annu Rev Biochem, 1995; 64:375-401.
84. Fernley RT. Non-cytoplasmic carbonic anhydrases. Trends Biochem Sci, 1988; 13:356-359.
85. Meier-Ruge W, Iwangoff P, Reichlmeier K. Neurochemical enzyme changes in Alzheimer’s and Pick’s disease. Arch Gerontol Geriatr, 1984; 3:161-165.
86. Choi J, Malakowsky CA, Talent JM, Conrad CC, Gracy RW. Identification of oxidized plasma proteins in Alzheimer’s disease. Biochem Biophys Res Commun, 2002; 293:1566-1570.
87. Korolainen MA, Goldsteins G, Alafuzoff I, Koistinaho J, Pirttila T. Proteomic analysis of protein oxidation in Alzheimer’s disease brain. Electrophoresis, 2002; 23:3428-3433.
88. Whitehouse PJ, Price DL, Clark AW, Coyle JT, Delong MR. Alzheimer’s disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol, 1981; 10:122-126.
89. Frolich L. The cholinergic pathology in Alzheimer’s disease — discrepancies between clinical experience and pathophysiological findings. J Neural Transm, 2002; 109:1003-1013.
90. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, Pepeu G, Casamenti F. Beta-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway. Neurobiol Dis, 2002; 11:257-274.
91. Boyd-Kimball D, Sultana R, Poon HF, Lynn BC, Casamenti F, Pepeu G, Klein JB, Butterfield DA. Proteomic identification of proteins specifically oxidized by intracerebral injection of Aβ (1-42) into rat brain: implications for Alzheimer’s disease. Neuroscience, 2005; 132:313-324.
92. Dougherty MK, Morrison DK. Unlocking the code of 14-3-3. J Cell Sci, 2004; 117:1875-1884.
93. Takahashi Y. The 14-3-3 proteins: gene, gene expression, and function. Neurochem Res, 2003; 28:1265-1273.
94. Fountoulakis M, Cairns N, Lubec G. Increased levels of 14-3-3 gamma and epsilon proteins in brain of patients with Alzheimer’s disease and Down syndrome. J Neural Transm, 1999; 57 (Suppl):323-335.
95. Burkhard PR, Sanchex JC, Landis T, Hochstrasser DF. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology, 2001; 56:1528-1533.
96. Layfield R, Fergusson J, Aitken A, Lowe J, Landon M, Mayer R. Neurofibrillary tangles of Alzheimer’s disease brains contain 14-3-3 proteins. Neurosci Lett, 1996; 209:57-60.
97. Hashiguchi M, Sobue K, Paudel HK. 14-3-3 zeta is an effector of tau protein phosphorylation. JBC, 2000; 275:25247-25254.
98. Hernández F, Cuadros R, Avila J. Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci Lett, 2004; 357:143-146.
99. Agarwal-Mawal A, Qureshi HY, Cafferty PW, Yuan Z, Han D, Lin R, Paudel HK. 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex. JBC, 2003; 278:12722-12728.
100. Li JY, Henning Jensen P, Dahlstrom A. Differential localization of a-, b-, and g-synucleins in the rat CNS. Neuroscience, 2002; 113:463-478.
101. Hashimoto M, Baron P, Ho G, Takenouchi T, Rockenstein E, Crews L, Masliah E. beta-Synuclein regulated Akt activity in neuronal cells: a possible mechanism for neuroprotection in Parkinson’s disease. J Biol Chem, 2004, 279:23622-23629, published online.
102. Poon HF, Calabrese V, Scapagnini G, Butterfield DA. Free radicals: Key to brain aging and heme oxygenase as a cellular response to oxidative stress. J Gerontol A: Biol Sci Med Sci, 2004; 59:478-493.
103. Calabrese V, Stella AM, Butterfield DA, Scapagnini G. Redox regulation in neurodegeneration and longevity: role of the heme oxygenase and HSP70 systems in brain stress tolerance. Antioxid Redox Signal, 2004; 6:895-913.
104. Bozner P, Wilson GL, Druzhyna NM, Bryant-Thomas TK, LeDoux SP, Wilson GL, MA. P. Deficiency of chaperonin 60 in Down’s syndrome. J Alzheimers Dis, 2002; 4:479-486.
105. Yoo BC, Kim SH, Cairns N, Fountoulakis M, Lubec G. Deranged expression of molecular chaperones in brains of patients with Alzheimer’s disease. Biochem Biophys Res Commun, 2001; 280:249-258.
106. Choi J, Malakowsky CA, Talent JM, Conrad CC, Carrll CA, Weintraub ST, Gracy RW. Anti-apoptotic proteins are oxidized by Ay8 25-35 in Alzheimer’s fibroblasts. Biochim Biophys Acta, 2003; 1637:135-141.
107. Butterfield DA, Howard BJ, Yatin S, Allen KL, Carney JM. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-alpha-phenylnitrone. Proc Natl Acad Sci USA, 1997; 94:674-678.
108. Kumar VB, Vyas K, Franko M, Choudhary V, Buddhiraju C, Alvarez J, Morley JE. Molecular cloning, expression, and regulation of hippocampal amyloid precursor protein of senescence accelerated mouse (SAMP8). Biochem Cell Biol, 2001; 79:57-67.
109. Rosenberg RN. The molecular and genetic basis of AD: The end of the beginning: the 2000 Wartenberg lecture. Neurology, 2000; 54:2045-2054.
110. Soreghan B, Thomas SN, Yang AJ. Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: potential pathological consequences in age-related neurodegeneration. Adv Drug Deliv Rev, 2003; 55:1515-1524.
111. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene, 1996; 180:157-163.
112. Wang LH, Strittmatter SM. A family of rat CRMP genes is differentially expressed in the nervous system. J Neurosci, 1996; 16:6197-6207.
113. Kato Y, Hamajima N, Inagaki H, Okamura N, Koji T, Sasaki M, Nonaka M. Post-meiotic expression of the mouse dihydropyrimidinase-related protein 3 (DRP-3) gene during spermiogenesis. Mol Reprod Dev, 1998; 51:105-111.
114. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene, 1996; 180:157-163.
115. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell, 1997; 90:739-751.
116. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. Cell, 1997; 90:753-762.
117. Luo Y, Raible D, Raper JA. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell, 1993; 75:217-227.
118. Goshima Y, Nakamura F, Strittmatter P, Strittmatter SM. Collapsin-induced growth cone collapse mediated by an intracellular protein related to UNC-33. Nature, 1995; 376:509-514.
119. Arimura N, Inagaki N, Chihara K, Menager C, Nakamura N, Amano M, Iwamatsu A, Goshima Y, Kaibuchi K. Phosphorylation of collapsin response mediator protein-2 by Rho-kinase. Evidence for two separate signaling pathways for growth cone collapse. J Biol Chem, 2000; 275:23973-23980.
120. Gu Y, Ihara Y. Evidence that collapsin response mediator protein-2 is involved in the dynamics of microtubules. J Biol Chem, 2000; 275:17917-17920.
121. Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shiromizu T, Watanabe H, Inagaki N, Iwamatsu A, Hotani H, Kaibuchi K. CRMP-2 binds to tubulin heterodimers to promote microtubule assembly. Nat Cell Biol, 2002; 4:583-591.
122. Yoshida H, Watanabe A, Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer’s disease. J Biol Chem, 1998; 273:9761-9768.
123. Weitzdoerfer R, Fountoulakis M, Lubec G. Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain. J Neural Transm Suppl, 2001; 61:95-107.
124. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Mol Psychiatry, 2000; 5:142-149.
125. Leto TL, Fortugno-Erikson D, Barton D, Yang-Feng TL, Francke U, Harris AS, Morrow JS, Marchesi VT, Benz EJ, Jr. Comparison of nonerythroid alpha-spectrin genes reveals strict homology among diverse species. Mol Cell Biol, 1988; 8:1-9.
126. Vanderklish PW, Bahr BA. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int J Exp Pathol, 2000; 81:323-339.
127. Harada J, Sugimoto M. Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res, 1999; 842:311-323.
128. Farr SA, Poon HF, Dogrukol-Ak D, Drake J, Banks WA, Eyerman E, Butterfield DA, Morley JE. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem, 2003; 84:1173-1183.
129. Butterfield DA, Hensley K, Cole P, Subramaniam R, Aksenov M, Aksenova M, Bummer PM, Haley BE, Carney JM. Oxidatively induced structural alteration of glutamine synthetase assessed by analysis of spin label incorporation kinetics: relevance to Alzheimer’s disease. J Neurochem, 1997; 68:2451-2457.
130. Poon H, Farr S, Thongboonkerd V, Lynn BC, Banks WA, Morley JE, Klein JB, DA B. Proteomic analysis of specific brain proteins in aged SAMP8 mice treated with alpha-lipoic acid: implications for aging and age-related neurodegenerative disorders. Neurochem Int, 2005; 46:159-168.
131. Boyd-Kimball D, Poon HF, Lynn BC, Cai J, Pierce WM, Klein JB, Ferguson J, Link CD, Butterfield DA. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Ab(1-42): implications for Alzheimer’s disease. Neurobiol Aging, 2005 (in press).
132. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, Perrino P. Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease. Arch Neurol, 1988; 45:836-840.
133. Aksenov M, Aksenova M, Butterfield DA, Markesbery WR. Oxidative modification of creatine kinase BB in Alzheimer’s disease brain. J Neurochem, 2000; 74:2520-2527.
134. Xie C, Lovell MA, Markesbery WR. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity. Free Radic Biol Med, 1998; 25:979-988.
135. Leiers B, Kampkotter A, Grevelding CG, Link CD, Johnson TE, Henkle-Duhrsen K. A stress-responsive glutathione S-transferase confers resistance to oxidative stress in Caenorhabditis elegans. Free Radic Biol Med, 2003; 34:1405-1415.
136. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem, 1997; 68:255-264.
137. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA. Apolipoprotein E modulates Alzheimer’s Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res, 2002; 924:90-97.
138. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer’s disease. Neurobiol Aging, 1998; 19:33-36.
139. Lovell MA, Xie C, Markesbery WR. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease. Neurology, 1998; 51:1562-1566.
140. Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S. Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience, 2002; 115:201-211.
141. Sullivan PG, Dragicevic NB, Deng JH, Bai Y, Dimayuga E, Ding Q, Chen Q, Bruce-Keller AJ, Keller JN. Proteasome inhibition alters neural mitochondrial homeostasis and mitochondria turnover. J Biol Chem, 2004; 279:20699-20707.
142. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer’s disease. J Neurochem, 2000; 75:436-439.
143. Jayarapu K, Griffin TA. Protein-protein interactions among human 20S protea-some subunits and proteassemblin. Biochem Biophys Res Commun, 2004; 314:523-528.
144. Eckert GP, Kirsch C, Leutz S, Wood WG, Muller WE. Cholesterol modulates amyloid beta-peptide’s membrane interactions. Pharmacopsychiatry, 2003; 36 (Suppl 2):S136-S143.